Get the Stockscreener App
3.23
0.47%
0.010
Xeris Biopharma Holdings Inc stock is traded at $3.23, with a volume of 975.03K.
It is up +0.47% in the last 24 hours and up +8.56% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
See More
Previous Close:
$3.22
Open:
$3.25
24h Volume:
975.03K
Relative Volume:
0.66
Market Cap:
$484.99M
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-6.2115
EPS:
-0.52
Net Cash Flow:
$-38.83M
1W Performance:
+0.15%
1M Performance:
+8.56%
6M Performance:
+71.16%
1Y Performance:
+70.26%
1-Day Range:
$3.10
$3.275
1-Week Range:
$3.10
$3.315
52-Week Range:
$1.46
$3.39
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Xeris Biopharma (XERS) Scheduled to Post Quarterly Earnings on Friday - MarketBeat
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 - BioSpace
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive - Seeking Alpha
SG Americas Securities LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
The Manufacturers Life Insurance Company Buys 5,291 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
The Xeris Biopharma Holdings Inc (XERS) had a good session last reading, didn’t it? - US Post News
Dimensional Fund Advisors LP Sells 6,437 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (XERS) looking to reclaim success with recent performance - SETE News
Market Recap Check: Xeris Biopharma Holdings Inc (XERS)’s Positive Finish at 2.97, Up/Down 2.06 - The Dwinnex
Xeris Biopharma Holdings Inc [XERS] Insider Activity: An Update for Investors - Knox Daily
Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips + - Seeking Alpha
Xeris Biopharma Holdings Inc [NASDAQ: XERS] Sees Decrease in Stock Value - Knox Daily
Ratio Review: Analyzing Xeris Biopharma Holdings Inc (XERS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Charting the Course: Xeris Biopharma Holdings Inc’s XERS Stock Prospects - The InvestChronicle
Several Insiders Invested In Xeris Biopharma Holdings Flagging Positive News - Yahoo Finance
Xeris Biopharma: Time For A Reassessment (NASDAQ:XERS) - Seeking Alpha
This trade activity should not be overlooked: Xeris Biopharma Holdings Inc (XERS) - SETE News
A year in review: Xeris Biopharma Holdings Inc (XERS)’s performance in the last year - US Post News
Xeris Biopharma Holdings Inc (XERS) Becoming More Attractive for Investors - Knox Daily
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
XERS Shares Experience Surge in Value - Knox Daily
XTX Topco Ltd Sells 223,267 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
XTX Topco Ltd Cuts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
Renaissance Technologies LLC Acquires 342,300 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Perhaps timely catching Xeris Biopharma Holdings Inc (XERS) would be a good idea - SETE News
Understanding the Risks of Investing in Xeris Biopharma Holdings Inc (XERS) - Knox Daily
Rhumbline Advisers Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Does Xeris Biopharma Holdings Inc (XERS) offer a good opportunity for investors? - SETE News
A company insider recently bought 4,515 shares of Xeris Biopharma Holdings Inc [XERS]. Should You Buy? - Knox Daily
Xeris Biopharma Holdings Inc (XERS) presents a great opportunity, but the stock is slightly overvalued - US Post News
A Guide To The Risks Of Investing In Xeris Biopharma Holdings Inc (XERS) - Knox Daily
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Bought by Bank of New York Mellon Corp - Defense World
Asset Management Group Inc. Acquires 15,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (XERS) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Xeris Biopharma Holdings Inc [XERS] Records 50-Day SMA of $2.58 - Knox Daily
Analytical Lens: Exploring Xeris Biopharma Holdings Inc (XERS)’s Financial Story Through Ratios - The Dwinnex
Financial Analysis: Lexaria Bioscience (NASDAQ:LEXX) & Xeris Biopharma (NASDAQ:XERS) - Defense World
Healthy Upside Potential: Xeris Biopharma Holdings Inc (XERS) - SETE News
Principal Financial Group Inc. Sells 10,992 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc [XERS] stock for 10,147 USD was bought by Schmid John P. - Knox Daily
Xeris Biopharma Holdings Inc [XERS] Revenue clocked in at $181.41 million, up 21.70% YTD: What’s Next? - The DBT News
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) most popular amongst individual investors who own 53% of the shares, institutions hold 43% - Yahoo Finance
XERS: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
The Potential Rise in the Price of Xeris Biopharma Holdings Inc (XERS) following insiders activity - Knox Daily
Xeris Biopharma Holdings Inc (XERS) requires closer examination - US Post News
Trading Day Review: Xeris Biopharma Holdings Inc (XERS) Gains Momentum, Closing at 2.67 - The Dwinnex
Allspring Global Investments Holdings LLC Boosts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks - Simply Wall St
Taking a look at what insiders are doing to gauge the Xeris Biopharma Holdings Inc (XERS)’s direction - Knox Daily
Xeris Biopharma Holdings Inc (XERS) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
A History of Outperforming Analyst Forecasts and Beating the Odds: Xeris Biopharma Holdings Inc (XERS) - SETE News
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xeris Biopharma Holdings Inc Stock (XERS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schmid John P. | Director |
Aug 09 '24 |
Buy |
2.37 |
4,285 |
10,134 |
20,685 |
| Schmid John P. | Director |
May 10 '24 |
Buy |
1.91 |
5,400 |
10,314 |
16,400 |
| JOHNSON JOHN | Director |
Mar 18 '24 |
Option Exercise |
1.99 |
215,600 |
429,044 |
751,412 |
| Schmid John P. | Director |
Mar 14 '24 |
Buy |
2.16 |
4,500 |
9,720 |
11,000 |
| SHERMAN JEFFREY W | Director |
Nov 27 '23 |
Buy |
1.87 |
5,400 |
10,098 |
5,400 |
| HALKUFF DAWN | Director |
Nov 20 '23 |
Buy |
1.84 |
5,410 |
9,954 |
5,410 |
| Pieper Steven | See Remarks |
Nov 20 '23 |
Buy |
1.95 |
28,000 |
54,600 |
1,176,912 |
| Schmid John P. | Director |
Nov 16 '23 |
Buy |
1.51 |
6,500 |
9,815 |
6,500 |
| Shannon John Patrick Jr | See Remarks |
Nov 17 '23 |
Buy |
1.64 |
30,769 |
50,400 |
1,408,575 |
| PERSKY MARLA | Director |
Nov 14 '23 |
Buy |
1.58 |
6,370 |
10,058 |
6,370 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):